Pacific Biosciences of California, Inc. (PACB) Balance Sheet

The erosion of equity from $649.0M in 2024Q1 to a deficit indicates that cumulative losses have consumed the company's entire book value. This negative equity position signals that liabilities now exceed assets, a fundamental weakening that increases reliance on external capital and constrains strategic flexibility.

The D/E ratio becoming undefined underscores the extreme leverage, with debt representing nearly 94% of total assets. This structure suggests that debt was incurred at a time when the company's equity cushion was more substantial, and now presents a material refinancing and solvency risk as the underlying business continues to generate losses.

The heavy weighting in goodwill, coupled with a declining asset base, suggests past acquisitions have not generated commensurate returns and may be overvalued on the current balance sheet. This concentration makes the company vulnerable to a non-cash impairment charge that would further deepen negative equity.

The scale of the retained earnings deficit dwarfs the company's total assets, implying that years of operating losses have created a massive hole that would require substantial and sustained profitability to fill. This deficit level severely limits options for capital returns and increases dependency on dilutive financing.